Inclusion Criteria:  NAFLD; defined by CAP >300 dB/m, liver stiffness >8Kpa and AST >30 U/dl. At least 2 features of Metabolic syndrome (defined by World Health Organization (WHO)). Stable medical and clinical condition. Age 18-80 years. BMI ≥25 Kg/m2. Diabetic on stable medical therapy for 6 months. Capable of providing written informed consent.  Exclusion Criteria:  Any known cause of liver disease other than NAFLD as confirmed by patient's history, laboratory data, and/or histological findings. Decompensated liver cirrhosis based on laboratory data and clinical manifestations (varices, ascites, or encephalopathy). Any previous experimental interventional treatment of NAFLD or NASH within the past 3 months. Pre-existing diseases/conditions that could interfere with the results or the completion of this trial based on the investigator's judgment. Unstable metabolic syndrome and other serious chronic medical conditions.  Unstable type 2 diabetes (any of the following):  Requiring medication adjustment within the last 3 months. Patients requiring GLP-1 agonists treatment. No more than 10% modification in insulin dose if on insulin. If on SGLT-2 inhibitors, need to be on stable dose with more than 5% weight loss in the last 3 months. Unable to adhere to out-patient clinic management program. Do not speak English on a daily-user level. Pregnant or planning to become pregnant within the following 6 months. Active substance use disorder. Does not accept follow-ups over 1 year from time of inclusion (T0). Inmates.